Mycoprotein (Quorn)

Fusarium venenatum (source fungus)
Evidence Level
Moderate
3 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

Mycoprotein is a fungal protein source produced by fermenting Fusarium venenatum (a microscopic fungus), commercialized primarily as Quorn. It's a complete protein with all essential amino acids and naturally high fiber content (roughly 6 g per 100 g serving). Here is what the cited evidence actually shows. A 7-day randomized trial in 20 healthy adults found a coordinated fall across 45 plasma lipid concentrations, and a trial in overweight and obese adults found lower energy intake and a lower postprandial insulin response. That same 7-day trial found no change in insulin sensitivity or 24-hour glycemic control. The amino acid profile is good — leucine content somewhat lower than whey but sufficient for muscle protein synthesis in adequate servings. Production is generally reported to have a lower environmental footprint than animal protein, which is an environmental point rather than a health effect and was not measured in any study cited here. The honest framing: a complete protein with a small evidence base, most of it produced by a single research group with links to the manufacturer, and useful mainly for people cutting meat while keeping high-quality protein intake. Read the safety section first, because published reports describe allergic reactions including anaphylaxis.

Studied Dose 90-180 g cooked mycoprotein per meal (11-22 g protein); consumed as a food.
Active Compound Mycoprotein - Fusarium venenatum mycelial biomass, ~45% protein and ~25% fiber (1,3/1,6-beta-glucan and chitin) by dry weight.

Benefits

LDL cholesterol reduction

Scope this carefully. The largest figures quoted on this page, total cholesterol down 6.74% and LDL down 12.3%, come from the Farsi 2023 crossover trial, which is not among this page's references and is therefore uncited here. What the cited evidence actually shows is a 7-day randomized trial in 20 healthy adults in which 45 plasma lipid concentrations fell by 7 to 27% (all P<0.05) when mycoprotein replaced meat and fish (32660657). That is a one-week lipidomic shift in a small group, not a demonstrated durable LDL reduction. The proposed reasons, more soluble fiber and less saturated fat than red meat, are plausible but were not tested directly.

Satiety and weight management

In a randomized controlled trial in healthy overweight and obese adults, a mycoprotein meal reduced energy intake at a later meal (27198187). The proposed reasons, high fiber content and texture, were not isolated in that trial. This is a short-term appetite finding, and no trial cited on this page measured body weight or body composition change, so nothing here shows weight loss.

Lower postprandial insulin, but no change in insulin sensitivity

Both results belong here. In overweight and obese adults, a mycoprotein meal lowered the postprandial insulin response without altering glucose (27198187). Over a longer window the result was null: in 20 healthy adults eating mycoprotein daily for 1 week there were no changes within or between groups in blood glucose, serum insulin, insulin sensitivity, or 24-hour glycemic profiles, and the paper is titled for that null finding (32660657). Nothing here supports use for any blood sugar condition.

Complete plant-based protein

Provides all essential amino acids in roughly the proportions needed for human protein synthesis. Two small randomized trials measured muscle protein synthesis rates, one in 20 resistance-trained young men (32438401) and one in 19 older adults (33172506). Both measured synthesis rates only. Neither measured strength, muscle size, endurance, or any exercise performance outcome, so nothing on this page shows improved performance. Leucine content per gram is lower than in whey or milk protein, which is why the young-men trial matched leucine by giving a larger serving of mycoprotein than of milk protein.

Environmental footprint, not a health effect

Mycoprotein production is generally reported to use less land and water and to produce fewer greenhouse gas emissions than animal protein. None of the studies cited on this page measured any environmental outcome, so this entry is uncited here. It is also an environmental consideration rather than a health benefit, and it is listed only because some buyers weigh it.

Mechanism of action

1

Bile acid sequestration and cholesterol reduction

Mycoprotein's fungal cell wall contains β-glucan (β-1,3/1,6, distinct from oat's β-1,3/1,4) and chitin — both viscous, fermentable fibers that bind bile acids in small intestine. Liver compensates by synthesizing more bile from cholesterol, depleting hepatic cholesterol pool. LDL receptor upregulation increases LDL clearance. Mechanism is similar to oat beta-glucan but with chitin contributing additional binding capacity.

2

Muscle protein synthesis via amino acid delivery

Mycoprotein provides a complete amino acid profile (PDCAAS ~0.99, comparable to milk and beef) with less leucine per gram than whey or milk protein; the trial cited here matched leucine by using a larger mycoprotein serving, 70 g supplying 31.5 g protein and 2.5 g leucine (32438401), so the practical serving is larger and there is no established 40 g protein threshold. The finding of more MPS than leucine-matched milk protein suggests possible additional effects beyond leucine, perhaps prebiotic/fiber-derived metabolites or unique fungal amino acid signaling not yet fully characterized.

3

Prebiotic/SCFA production from fungal fiber

Chitin and β-glucan from fungal cell walls are fermented by colonic bacteria producing short-chain fatty acids (acetate, propionate, butyrate). Shifts in Bifidobacteria and Faecalibacterium prausnitzii have been reported elsewhere, but no reference on this page measured the gut microbiome or short-chain fatty acid production. May contribute to anti-inflammatory effects, gut health, and possibly indirect metabolic benefits.

4

Glycemic load reduction (viscous fiber gel)

β-glucan and chitin form viscous gel in stomach/small intestine, slowing gastric emptying and glucose diffusion. This is the proposed mechanism, and it did not produce the expected results in the cited trials: the acute trial found lower insulin with no change in glucose (27198187), and the 1-week trial found no change in insulin sensitivity or 24-hour glycemia (32660657). Treat the comparison with oat beta-glucan as a hypothesis rather than a demonstrated equivalence.

Clinical trials

1
Mycoprotein vs Milk Protein, Muscle Protein Synthesis

Randomized double-blind parallel-group trial (Monteyne AJ, Coelho MOC, Porter C, Abdelrahman DR, Jameson TSO, Jackman SR, Blackwell JR, Brook MS, Murton AJ, Alamdari N, Stephens FB, Wall BT 2020, Am J Clin Nutr 112(2):318-333, doi:10.1093/ajcn/nqaa092).

20 resistance-trained healthy young males (age 22 ± 1 y, BMI 25 ± 1) under primed continuous L-[ring-2H5]phenylalanine infusion. Ingested either 31 g milk protein (26.2 g protein, 2.5 g leucine) or 70 g mycoprotein (31.5 g protein, 2.5 g leucine — leucine-matched) following unilateral resistance exercise (contralateral leg as resting control).

Single bolus of mycoprotein stimulated resting and post-exercise muscle protein synthesis to a greater extent than leucine-matched bolus of milk protein. Statistically significant superiority of mycoprotein vs milk protein in both rested and exercised muscle. Read the limits with the result. The outcome was a muscle protein synthesis rate after a single serving, not strength, muscle size, or any exercise performance measure, so this trial says nothing about athletic performance. It ran in 20 resistance-trained young men, and the research group has links to the manufacturer. A higher synthesis rate after one serving is a short-term surrogate and does not by itself establish more muscle gained over time.

2
Mycoprotein Symposium Review

Uncited on this page: this 2019 symposium paper is not among the references listed below, so the figures summarized in this card have not been checked against a source here. A symposium paper is also a narrative review rather than a systematic review or a trial.

Review of mycoprotein clinical literature — 13 human studies investigating health properties of mycoprotein.

Documented evidence of: (1) sustained satiety (multiple acute meal trials), (2) improved metabolic profiling — 5 of 9 trials found improved blood lipid levels, with cholesterol reductions 9-13% in meaningful intervention trials, (3) muscular protein synthetic response equivalent to milk/whey, (4) glucose and insulin control benefits, (5) an assertion of low allergic reaction incidence. That last point should be read against the 2018 adverse-reaction analysis now in the references below, which describes 1,752 self-reported complaints including 312 allergic reactions and one fatal reaction. Neither source can establish an incidence rate. The review concluded that mycoprotein has nutritional and environmental advantages; its authorship overlaps with the manufacturer-linked group that produced most of the trials cited on this page.

3
Mycoprotein vs Red/Processed Meat

Uncited on this page: this 2023 trial is not among the references listed below, so the percentages in this card have not been verified against a source here.

20 metabolically healthy adult males consumed 240 g/day red and processed meat for 14 days followed by mycoprotein, OR vice versa (crossover design). Blood biochemical indices were a priori secondary endpoints.

Mycoprotein consumption reduced total cholesterol by 6.74% (p=0.02) and LDL cholesterol by 12.3% (p=0.02) from baseline. Triglycerides not significantly different (+0.19 mmol/L, p=0.09). Because this trial is not among the page's references, treat these percentages as unverified here. They also come from a priori secondary endpoints in 20 metabolically healthy men over 14 days, which is a short exposure in a small and narrow group, and triglycerides did not change significantly.

Side effects and drug interactions

Common Potential side effects

Most people tolerate mycoprotein, and it is sold as a food in many countries. Wide availability is not the same as safety data, so read the reaction reports below before a first serving.
GI symptoms when first introduced: bloating, flatulence, occasional nausea — usually resolve within 1-2 weeks of regular consumption.
Allergic reactions: a 2018 analysis in Annals of Allergy, Asthma and Immunology reviewed 1,752 self-reported adverse-event reports about mycoprotein-containing foods. Of those, 312 reported allergic reactions including hives and anaphylaxis; reactions began within 4 hours and 45.8% within 1 hour, and one fatal reaction is described (29567357). The limitations carry equal weight: these were self-reported complaints submitted through a website run by an advocacy organization, there is no denominator, and the data therefore cannot establish how often reactions occur or how the risk compares with any other food.
Fungal allergy: if you have a known allergy to Fusarium or other fungi, speak with a clinician before trying mycoprotein. Treat this as a precaution; it is not a risk factor that the published reaction reports identified.
FODMAP content: may not be suitable for those on low-FODMAP diets due to fungal carbohydrates.

Important Drug interactions

Statins: complementary cholesterol-lowering; theoretical additive effect, monitor.
Diabetes medications: theoretical only. The cited trials found no change in blood glucose, so a meaningful additive effect is unlikely, though any large dietary change is worth raising with the prescriber.
Most medications: no significant pharmacological interactions documented.
Iron/zinc supplements: high fiber content may modestly reduce absorption — separate by 1-2 hours.
Compatible with most cardiovascular and metabolic medications.

Frequently asked questions about Mycoprotein (Quorn)

What is mycoprotein?

Mycoprotein is a complete protein made from a fungus (Fusarium venenatum), best known as the base of Quorn products. It is high in protein and fiber and is largely plant-based (some products contain egg).

Is mycoprotein a good protein source?

Yes. Mycoprotein is a complete protein with all essential amino acids, plus fiber. Small trials show it raises muscle protein synthesis rates at least as much as milk protein, but those trials measured synthesis rates rather than strength or muscle gained. Other short trials report lower energy intake at a later meal and a fall in plasma lipid concentrations over 1 week.

How much mycoprotein should I eat?

It is usually eaten as a food (like Quorn) rather than a measured supplement. A typical serving provides around 15 to 20 grams of protein along with several grams of fiber.

Does mycoprotein cause digestive issues?

Bloating and gas are common in the first week or two and usually settle. Allergic reaction is the more serious concern: a 2018 analysis of self-reported complaints described hives, anaphylaxis, and one fatal reaction, with onset within 4 hours and 45.8% of allergic reactions starting within an hour of eating. Those complaints were submitted to a website run by an advocacy organization and have no denominator, so they cannot tell you how likely a reaction is, but they are a good reason to start with a small serving and to seek emergency care for breathing difficulty, swelling, or widespread hives.

What is Mycoprotein used for?

Mycoprotein is researched primarily for Cardiovascular, Muscle & Recovery, and Weight Management. Scope this carefully. The largest figures quoted on this page, total cholesterol down 6.74% and LDL down 12.3%, come from the Farsi 2023 crossover trial, which is not among this page's references and is therefore uncited here.

What is the recommended dosage of Mycoprotein?

The clinically studied dose is 90-180 g cooked mycoprotein per meal (11-22 g protein); consumed as a food. Always follow the product label and check with a healthcare provider for personal advice.

Is Mycoprotein safe, and does it have side effects?

For most healthy adults, Mycoprotein is well tolerated at studied doses. Reported effects can include: Most people tolerate mycoprotein, and it is sold as a food in many countries. Wide availability is not the same as safety data, so read the reaction reports below before a first serving. It may also interact with some medications. Mycoprotein is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Mycoprotein interact with any medications?

Possible interactions include: Statins: complementary cholesterol-lowering; theoretical additive effect, monitor. Diabetes medications: theoretical only. The cited trials found no change in blood glucose, so a meaningful additive effect is unlikely, though any large dietary change is worth raising with the pre… If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Mycoprotein?

NutraSmarts rates the evidence for Mycoprotein as Moderate (3 out of 5). It is backed by 3 clinical trials and 5 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(5 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Coelho MOC, Monteyne AJ, Dirks ML, Finnigan TJA, Stephens FB, Wall BT Daily mycoprotein consumption for 1 week does not affect insulin sensitivity or glycaemic control but modulates the plasma lipidome in healthy adults: a randomised controlled trial The British Journal of Nutrition. 2021;125(2):147-160. doi: 10.1017/S0007114520002524.PubMedUsed to support: RCT showing mycoprotein favorably modulated the plasma lipidome (consistent with LDL-cholesterol-lowering effects seen elsewhere); supports the cholesterol/lipid benefit, while honestly noting it did not change insulin sensitivity over one week and is from a research group linked to the manufacturer.
  2. Bottin JH, Swann JR, Cropp E, Chambers ES, Ford HE, Ghatei MA, et al. Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial The British Journal of Nutrition. 2016;116(2):360-74. doi: 10.1017/S0007114516001872.PubMedUsed to support: RCT in overweight/obese adults showing mycoprotein increased satiety and reduced subsequent energy intake and postprandial insulin; supports the satiety/appetite-control benefit (trials remain relatively few).
  3. Monteyne AJ, Coelho MOC, Porter C, Abdelrahman DR, Jameson TSO, Jackman SR, et al. Mycoprotein ingestion stimulates protein synthesis rates to a greater extent than milk protein in rested and exercised skeletal muscle of healthy young men: a randomized controlled trial The American Journal of Clinical Nutrition. 2020;112(2):318-333. doi: 10.1093/ajcn/nqaa092.PubMedUsed to support: RCT showing mycoprotein stimulated muscle protein synthesis at least as well as (here, more than) milk protein in young men; supports mycoprotein as an effective muscle-supporting protein source, though it is a small study from a manufacturer-linked group.
  4. Monteyne AJ, Dunlop MV, Machin DJ, Coelho MOC, Pavis GF, Porter C, et al. A mycoprotein-based high-protein vegan diet supports equivalent daily myofibrillar protein synthesis rates compared with an isonitrogenous omnivorous diet in older adults: a randomised controlled trial The British Journal of Nutrition. 2021;126(5):674-684. doi: 10.1017/S0007114520004481.PubMedUsed to support: RCT in older adults showing a mycoprotein-based vegan diet supported daily myofibrillar protein synthesis equivalent to an omnivorous diet; supports the claim that mycoprotein backs muscle protein synthesis comparably to animal protein, with the caveat of small, manufacturer-linked trials.
  5. Jacobson MF, DePorter J. Self-reported adverse reactions associated with mycoprotein (Quorn-brand) containing foods. Ann Allergy Asthma Immunol. 2018;120(6):626-630. doi: 10.1016/j.anai.2018.03.020.PubMedUsed to support: Ann Allergy Asthma Immunol 2018;120(6):626-630 (Jacobson MF, DePorter J). Analysis of 1,752 self-reported adverse-event reports submitted through a web questionnaire; 312 reported allergic reactions including urticaria and anaphylaxis, with onset within 4 hours and 45.8% within 1 hour, and one fatal reaction described. Gastrointestinal symptoms occurred within 8 hours. Limitations that must be read alongside those numbers: the reports are self-reported complaints submitted to a website run by an advocacy organization, there is no denominator, and the data cannot establish incidence, risk, or any comparison with other allergenic foods.